SNPHF (Santen Pharmaceutical Co) Interest Expense: $-13 Mil (TTM As of Mar. 2026)

What is Santen Pharmaceutical Co Interest Expense?

Santen Pharmaceutical Co SNPHF +4.40% 81 Interest Expense is $-13 Mil as of Mar. 2026. GuruFocus rates SNPHF with a GF Score™ of 81/100 and a GF Value™ of $10.25 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Santen Pharmaceutical Co's interest expense for the three months ended in Mar. 2026 was $ -3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-13 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Santen Pharmaceutical Co's Operating Income for the three months ended in Mar. 2026 was $ 123 Mil. Santen Pharmaceutical Co's Interest Expense for the three months ended in Mar. 2026 was $ -3 Mil. Santen Pharmaceutical Co's Interest Coverage for the quarter that ended in Mar. 2026 was 38.24. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Santen Pharmaceutical Co (OTCPK:SNPHF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Santen Pharmaceutical Co's Interest Expense for the three months ended in Mar. 2026 was $-3 Mil. Its Operating Income for the three months ended in Mar. 2026 was $123 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0 Mil.

Santen Pharmaceutical Co's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2026 )	/	Interest Expense (Q: Mar. 2026 )
	=	-1	*	123.391	/	-3.227
	=	38.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Santen Pharmaceutical Co Interest Expense Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Interest Expense can be seen below:

Santen Pharmaceutical Co Interest Expense Chart

Santen Pharmaceutical Co Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

Interest Expense

Get a 7-Day Free Trial

-10.20

-11.22

-17.78

-18.22

-12.57

Santen Pharmaceutical Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-9.39	-5.18	-2.81	-2.04	-3.23

81GF Score

Santen Pharmaceutical Co Ltd SNPHF

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Santen Pharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-13 Mil mean?

Santen Pharmaceutical Co (SNPHF) has a Interest Expense of $-13 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Santen Pharmaceutical Co and its competitors.

Is Santen Pharmaceutical Co's Interest Expense too high?

Santen Pharmaceutical Co's current Interest Expense is $-13 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Santen Pharmaceutical Co's Interest Expense compare to LLY and JNJ?

Santen Pharmaceutical Co's Interest Expense of $-13 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Drug Manufacturers company?

A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Interest Expense is $-13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Santen Pharmaceutical Co stock overvalued right now?

Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.25, compared to a current price of $13.05 — trading 27.3% above its estimated fair value. The current Interest Expense is $-13 Mil. Santen Pharmaceutical Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Interest Expense is $-13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 27.3% above its estimated GF Value™ of $10.25. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

Interest Expense: $-13 Mil
GF Value™: $10.25 vs. price of $13.05 (27.3% above fair value)
GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TSE:4528 TSE:4552 TSE:4882 LLY JNJ ABBV XSWX:ROP MRK XSWX:NOVN LSE:AZN OCSE:NOVO B AMGN GILD PFE BMY LSE:GSK XPAR:SAN TSE:4519 XTER:BAYN TSE:4578

Other Exchanges SNPHY:USA 4536:Japan

Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552

Website https://www.santen.com

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.

81GF Score

Get the complete analysis for SNPHF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05

Price

$10.25

GF Value

View SNPHF Analysis

See Interest Expense data for all stocks →